The Amgen v. Sanofi dispute over cholesterol-lowering antibody patents resulted in a #SCOTUS ruling in May that some argue may inhibit biotechnology innovation. Partner Laura Smalley of our Intellectual Property Law Practice Group says in Nature Biotechnology, a monthly peer-reviewed scientific journal, that research institutes and startups may feel the greatest impact. “Basic research and initial proof of concept, no matter how groundbreaking it is, will be more difficult to protect,” Smalley tells reporter Charlotte Harrison.

Nature Biotechnology is a part of Nature Portfolio, an international scientific publishing company dating back to 1869. Read more of Charlotte’s article and Laura’s comments here: https://rdcu.be/djqXH